The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...
Telemedicine helps Parkinson’s patients—safe, effective rehab via video calls. Discover the TELEPARK trial’s promising results.
Higher coffee consumption is causally linked to delayed onset of Parkinson’s disease but does not affect disease risk or ...
Scientists at La Jolla Institute for Immunology (LJI) have found a potential new target for treating Parkinson's disease.
The FDA has approved BrainSense, an adaptive deep brain stimulation system that can adjust therapy for Parkinson’s disease in ...
The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...
(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.
Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...
Chinese researchers have identified a new therapeutic target for Parkinson's disease, a neurodegenerative disorder with high disability and mortality rates, and have successfully discovered a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results